Don't wanna be here? Send us removal request.
Statistics
We looked inside some of the posts by rootsanalysis-blog and here's what we found interesting.
Average Info
Notes Per Post
1
Likes Per Post
1
Reblog Per Post
0
Reply Per Post
0
Time Between Posts
3 days
Number of Posts By Type
Text
17
Last Seen Tumblr Blogs
Fun Fact
When “GIF” was named word of the year in 2012, Oxford Dictionaries U.S.A. credited Tumblr for pushing the word.
Text
Manufacturing Execution System Providers in Healthcare Market
Every year, the healthcare industry generates a massive amount of data. In fact, the healthcare data currently constitutes around 30% share of the global data volume. Further, it is estimated that, by 2025, the data generated via the healthcare sector will rise at a compound annual growth rate of 36%.
It is important to consider that the constant management of such enormous volumes of data is a quite tedious process and challenging process. Specifically, management and handling of huge datasets in the healthcare industry often requires a large workforce of specialized personnel. According to the American Hospital Association, by 2026, there is likely to be a shortage of 3.2 million healthcare workers. The continuously growing data, coupled to the projected deficit of healthcare workers, would inadvertently generate pressure on healthcare manufacturers to adopt novel tools / technologies that can improve management efficiency and better utilize the available, expensive resources. Moreover, increasing complexity of healthcare manufacturing operations, along with growing stringency and frequent changes in regulatory requirements has created a dire need for adoption of automated solutions, such as manufacturing execution systems (MES). It is worth mentioning that, in the past few years, substantial acquisition activity has been reported in the manufacturing execution systems market, as players strive to become one-stop-shops, to cater to the diverse needs of the healthcare sector.
To request a sample copy / brochure of this report, please visit
https://www.rootsanalysis.com/reports/manufacturing-execution-systems-market/request-sample.html
In recent years, several healthcare stakeholders have actively undertaken initiatives to incorporate a manufacturing execution system into their production lines, with an aim to connect, monitor and control the complex manufacturing process. In addition, players are integrating advanced technologies, including internet of thing (IoT) and artificial intelligence (AI), in order to collect and analyze large volume of data from various sources, as well as to produce value in the form of insights, predictions and actions. According to industry experts, MES has the potential to reduce 10%-30% of the overall production cost depending on the type of industry. It has further been observed that companies are increasingly adopting cloud-based manufacturing execution system, to overcome the challenges associated with growing complexity of processes and global expansion of businesses. Specifically, cloud-based MES integrates real-time information of different production floors and promotes collaboration. Driven by the ongoing innovation in the industry, as well as the rise in demand for automated solutions, the manufacturing execution system providers market for the healthcare sector is likely to witness positive growth over the coming years.
For additional details, please visit
https://www.rootsanalysis.com/reports/manufacturing-execution-systems-market.html or email [email protected]
You may also be interested in the following titles:
1. Targeted protein degradation market, 2022-2035
2. Single-Use Upstream Bioprocessing Technology / Equipment Market, 2022-2035
About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector.
Contact:
Ben Johnson
+1 (415) 800 3415
+44 (122) 391 1091
#manufacturing execution systems#manufacturing execution systems market#manufacturing execution#MES#Market Research#Market Insights#RootsAnalysis
0 notes
Text
The clinical trials software market is projected to be growing at a CAGR of 14%
Given the limitations of current clinical trial approaches, including inefficient patient management and data handling, trial sponsors are increasingly opting for innovative technologies and software solutions for conducting clinical trials
Roots Analysis has announced the addition of “Clinical Trials Software Market, 2022-2035” report to its list of offerings.
Excessive capital expenditure and other complexities associated with the traditional clinical trials has imposed an enormous financial burden on the pharmaceutical industry. Virtual clinical trials software solutions have the potential to induce substantial digital changes in clinical research methodology, resulting in a more patient-centric, cost-effective and easy to manage approach.
To order this 270+ page report, which features 60+ figures and 50+ tables, please visit https://www.rootsanalysis.com/reports/clinical-trial-software-market.html
Key Market Insights
Over 70+ companies claim to provide clinical trials software
The companies offer clinical trials software with different features like electronic data capture, eCOA/ePRO and eConsent along with decentralized and virtual clinical trials and remote monitoring of the patients. Majority of the players based in North America offer clinical trials software followed by Europe and Asia-Pacific. Further, the market is dominated by the presence of mid-sized players (more than 40%) followed by small and large players.
Clinical trial management software
It is a well-known fact that clinical trials form an integral part of the overall drug development process, enabling innovators to assess safety and efficacy of their drug candidates / devices. These studies account for around 50% of the total time and capital invested in the development process
Since 2016, more than 120+ partnerships have been inked by service providers
Interestingly, the maximum number of partnership agreements were inked in 2021, majority of these were service agreements (44%), followed by acquisitions/mergers (26%). Further, most of the deals were inked with players based in North America (64%).
Over 30 mergers and acquisitions were reported in this domain, during the period 2016-2021
More than 85% of these were instances of acquisitions. Further, majority of the instances involved the companies based in North America and the maximum number of deals were inked in 2019.
Over USD 492.8 million has been invested by both private and public investors, since 2016
Majority of the companies (67%) engaged in this domain primarily received funding through venture capital rounds. Further, around 98% of the funding instances were reported by players headquartered in North America.
The market is expected to grow at an annual rate close to 14% over the coming decade
The opportunity is likely to be well distributed across clinical trials software on the basis of features of software (EDC, eCOA/ePRO and eConsent) and geographies (North America, Europe and Asia-Pacific). By 2035, the clinical trials software market in North America is anticipated to grow at a relatively faster pace (39%), followed by the market in Europe (21%).
Clinical trial management system : Driven by the substantial progress in this domain, encouraging virtual clinical trial results, and ongoing technological advancement, the clinical trials software market is anticipated to grow at a commendable pace in the mid to long term.
To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/clinical-trial-software-market/request-sample.html
Key Questions Answered
§ Who are the leading players engaged in the development of clinical trials software solutions?
§ Which region(s) will occupy the maximum market share in clinical trials software domain?
§ Who are the key venture capitalists / strategic investors funding the clinical trials software development initiatives?
§ Which partnership models are commonly adopted by stakeholders engaged in the development of clinical trials software solutions?
§ Which factors are likely to influence the evolution of this market?
§ How is the current and future market opportunity likely to be distributed across key market segments?
By 2035, the financial opportunity within the clinical trials software market has been analysed across the following segments:
§ Features of Software
§ Electronic Data Capture
§ eCOA/ePRO
§ eConsent
§ Analysis by Geographical Regions
North America
Europe
Asia Pacific
The research includes profiles of key players (listed below); each profile features a tabulated overview of company, product portfolio, recent developments, and an informed future outlook.
§ Advarra
§ ArisGlobal
§ AssistRx
§ Clario
§ IBM
§ IQVIA
For additional details, please visit
https://www.rootsanalysis.com/reports/clinical-trial-software-market.html or email [email protected]
You may also be interested in the following titles:
1. Virtual Clinical Trial Service Providers Market, 2021-2030
2. AI-based Clinical Trial Solutions Providers Market, 2020-2030
3. Patient Recruitment and Retention Services Market (2nd Edition), 2021-2030
4. Virtual Clinical Trial Service Providers Market, 2020-2050
About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected]
Contact:
Ben Johnson
+1 (415) 800 3415
+44 (122) 391 1091
#clinical trial management system#clinical trial management software#clinical trials software market#clinical trials software#Market Research#Market Insights#RootsAnalysis
0 notes
Text
The container closure integrity testing services market is projected to grow at a CAGR of 7% till 2035
Patient safety is one of the critical aspects of pharmaceutical industry, which makes it imperative for drug manufacturers and packaging service providers to evaluate the integrity of drug formulations packed in various container closure systems
Roots Analysis has announced the addition of “Container Closure Integrity Testing Services Market, 2022-2035” report to its list of offerings.
The report features an extensive study on the extensive study of the current landscape and the likely future potential of container closure integrity testing services, over the next decade. The study also features an in-depth analysis, highlighting the capabilities of various industry stakeholders engaged in this field. In addition to other elements, the study includes:
§ A detailed assessment of the overall market landscape of container closure integrity testing service providers based on a number of relevant parameters. In addition, it presents details of the companies, highlighting their year of establishment, company size, and geographical presence.
§ A detailed competitiveness analysis of container closure integrity testing service providers, taking into consideration several relevant parameters.
§ Tabulated profiles of the key players providing container closure integrity testing services, which are headquartered in North America and Europe. Each profile includes an overview of the company, information on the financial performance (if available), product portfolio, recent developments, and an informed future outlook.
§ A case study providing the list of equipment used by various manufacturers to test container closure integrity, highlighting their key features, type(s) of analytical method(s) offered, type(s) of container(s) tested, container material(s) of container closure integrity testing technologies.
§ A detailed competitiveness analysis of container closure integrity testing equipment, taking into consideration several relevant parameters.
§ A regional capability assessment framework, which compares the container closure integrity testing capability across key geographies, based on a number of parameters.
§ A detailed analysis of the various container closure integrity testing analytical techniques. It highlights the popularity of analytical techniques and offers a benchmark to compare analytical techniques.
§ A case study on the use of robotic machinery in pharmaceutical manufacturing and fill / finish operations, highlighting the advantages of using automation / automated technologies in such processes. Further, it presents the profiles of industry players that provide such equipment for aseptic processing of pharmaceuticals.
§ An in-depth analysis to estimate the current and future demand of container closure integrity testing service based on various relevant parameters.
§ A discussion on affiliated trends, key drivers and challenges, under a comprehensive SWOT framework, which are likely to impact the industry’s evolution, including a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall industry.
§ By 2035, the financial opportunity within the container closure integrity testing services market has been analyzed across the following segments:
§ Analysis by Type of Container Closure System
Vials
Syringes
Cartridges
§ Analysis by Type of Container Material
Glass
Plastic
§ Analysis by Geographical Regions
North America
Europe
Press Release: Variation 1 (Format 2)
Europe
Asia Pacific
MENA
Latin America
Rest of the World
Europe
Asia Pacific
MENA
Latin America
Rest of the World
Key companies covered in the report:
§ Berkshire Sterile Manufacturing
§ Confarma
§ Curia
§ DDL
§ Eurofins
§ Nelson Labs
§ SGS
§ Stevanato Group
§ Wilco
For more information, please click on the following link:
https://www.rootsanalysis.com/reports/container-closure-integrity-testing-services-market.html
Other recent offerings:
1. Sustainable, Biodegradable and Eco-Friendly Packaging Providers Market: Industry Trends and Global Forecast, 2021-2035
2. Novel Drug Reconstitution Systems Market: Industry Trends and Global Forecast, 2021-2030
3. Global Pharmaceutical Vials Market: Industry Trends and Global Forecasts, 2021-2030
4. Cell Therapy Packaging Products and Services Market: Industry Trends and Global Forecast, 2021-2030
5. Pre-Sterilized / Ready-to-Use Primary Packaging Market: Industry Trends and Global Forecast, 2021-2030
About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected]
Contact Information
Roots Analysis Private Limited
Ben Johnson
+1 (415) 800 3415
#Container Closure Integrity (CCI)#container closure integrity testing#packaging testing market#integrity test market.#Market Research#Market Insights#RootsAnalysis
0 notes
Text
The global digital therapeutics market is projected to be worth over USD 8.86 billion by 2030, growing at a CAGR of 19.7%
Recent advances in information technology and biomedical science have enabled the development of a number of versatile digital solutions that are capable of either mimicking or augmenting, the fundamental qualities of pharmacological interventions
Roots Analysis has announced the addition of “Digital Health Market: Focus on Digital Therapeutics (2nd Edition), 2020-2030 (Based on Type of Solution (Software Solution, Gaming Solution and Combination Solution), Type of Therapy (Curative and Preventive), and Purpose of Solution (Medication Replacement and Medication Augmentation” report to its list of offerings.
According to experts, digital therapeutic solutions are primarily based on behavior modification and are designed to address a variety of therapeutic needs across a wide range of disease indications. On the other hand, several digital solutions have been developed to enable remote doctor-patient consultations. Such solutions witnessed a surge in adoptions amidst the COVID-19 pandemic.
To order this 500+ page report, which features 160+ figures and 200+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/digital-health-market/208.html
Key Market Insights
Nearly 230 digital therapeutic solutions are currently available / under development
Close to 45% of the aforementioned solutions are standalone software applications targeting more than 60 unique indications.
Over 85% of digital therapeutic solutions are intended to replace medication
Such solutions are currently available / being developed to treat neurological disorders (27%), mental health problems (24%), and certain metabolic disorders (24%). Alternatively, some digital health products are designed to augment the effect of conventional therapeutics and are currently being considered for treating substance use disorders and few mental health problems.
220+ clinical trials, focused on digital therapeutics, have been registered since 2004
Around 80,000 patients have been enrolled in clinical research initiatives aimed to validate the efficacy of digital therapeutics, and generate real world evidence concerning their efficacy and safety. Close to 50% of such trials have been / are being conducted in the US.
Nearly USD 1.9 billion invested by both private and public investors in this domain
~85% of the total capital raised for digital therapeutics-related initiatives was from venture capital investors, featuring over 370 participants.
Partnership activity in this field has grown at a CAGR of ~42%, between 2015 and 2019
More than 70% of the reported deals were established after 2017, with the maximum activity being reported in 2019. Majority of the instances captured in the report were focused on pilot product offering (29%) and research and development agreements (21%).
North America and Europe are anticipated to capture over 70% of the market share by 2030
The market in Asia-Pacific regions is anticipated to grow at a relatively faster pace (23.2%). In 2030, digital solutions targeting metabolic disorders are likely to represent the largest market share, in terms of revenues from product sales (26%), followed by those intended for mental health problems (20%) and neurological disorders (19%).
To request a sample copy / brochure of this report, please visit this - https://www.rootsanalysis.com/reports/208/request-sample.html
One of the key objectives of the report was to estimate the existing digital health market size and the future opportunity for digital therapeutics developers over the next decade.
A discussion on affiliated digital health market trends, key drivers and challenges, under a SWOT framework, which are likely to impact the industry’s evolution.
Key Questions Answered
§ Who are the leading players engaged in the development of digital therapeutic solutions?
§ What are the most popular therapeutic areas addressed by digital health solutions?
§ What are the key factors influencing the price of digital therapeutics?
§ What is the trend of capital investments in the digital therapeutics market?
§ Which partnership models are commonly adopted by stakeholders in this industry?
§ What type of marketing strategies are being adopted by developers in this domain?
§ How is the COVID-19 pandemic likely to impact the digital therapeutics market?
§ How is the current and future opportunity likely to be distributed across key market segments?
§ What are the anticipated future trends related to digital therapeutics?
The USD 8.86 billion (by 2030) financial opportunity within the digital therapeutics market has been analyzed across the following segments:
§ Type of Solution
§ Standalone Software Application
§ Software Application + Device + Personal Coach
§ Software Application + Device + AI Support
§ Software Application + Device
§ Software Application + AI Support
§ Software Application + Personal Coach
§ Other Types of Solutions
§ Purpose of Solution
§ Medication Replacement
§ Medication Augmentation
§ Type of Therapy
§ Curative
§ Preventive
§ Business Model
§ Business to Consumer (Patients and Caregivers)
§ Business to Business (Healthcare Providers, Payers, Employers and Pharmaceutical Companies)
§ Therapeutic Areas
§ Cardiovascular Disorders
§ Chronic Pain
§ Mental Health Problems
§ Metabolic Disorders
§ Neurological Disorders
§ Respiratory Disorders
§ Sleep Disorders
§ Substance Use Disorders
§ Others
§ Key Geographical Regions
§ North America
§ Europe
§ Asia-Pacific
§ Rest of the world
The report features inputs from eminent industry stakeholders, according to whom, digital therapeutic solutions are likely to witness enhanced adoption due to their broader applicability, remote guidance and other advanced features, thereby, offering lucrative opportunities to their developers. The report includes detailed transcripts of the discussions held with following industry experts:
§ Eran Ofir (Co-Founder and Chief Executive Officer, Somatix)
§ Edouard Gasser (Co-Founder and Chief Executive Officer, Tilak Healthcare)
§ Stephanie Tilenius (Co-Founder and Chief Executive Officer, Vida Health)
§ Adam Kaufman (Chief Executive Officer, Canary Health)
§ Vijay Ravindran (Chief Executive Officer, Floreo)
§ Palakh R Sarogi (Vice President, Marketing, Wellthy Therapeutics), Arani Sarkra (Senior Manager, Consumer Marketing, Wellthy Therapeutics) and Yolande D’Mello (Marketing and Public Relations, Wellthy Therapeutics)
§ Amelie Janson (Communication Manager, Voluntis)
§ Anonymous (Founder and Chief Executive Officer, UK based Small-sized Company)
The research covers brief profiles of key players engaged in the development of digital therapeutic solutions; other popular industry players featured in the report include:
§ Akili Interactive
§ Beats Medical
§ Big Health
§ Bold Health
§ Click Therapeutics
§ CureApp
§ dreem
§ Ehave
§ Ginger
§ Happify Health
§ inMotion VR
§ Kaia Health
§ Lark Health
§ Mahana Therapeutics
§ MindMaze
§ Noom
§ NOVOSI
§ Omada Health
§ Palo Alto Health Sciences
§ Pear Therapeutics
§ Vida Health
§ Welldoc
§ ZOLL Medical
For additional details, please visit
https://www.rootsanalysis.com/reports/view_document/digital-health-market-focus-on-digital-therapeutic-monitoring-and-diag/208.html
You may also be interested in the following titles:
1. AR / VR Based Healthcare Digital Marketing Service Providers Market, 2020-2030
2. AI-Based Clinical Trial Solution Providers Market, 2020-2030
3. Global Handheld Ultrasound Imaging Devices Market, 2020-2030
About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected]
Contact:
Ben Johnson
+1 (415) 800 3415
+44 (122) 391 1091
#digital health#digital health market#digital health market size#digital health market trends#Market Research#Market Insights#RootsAnalysis
1 note
·
View note
Text
RNAI THERAPY OFFERS THE POTENTIAL TO REVOLUTIONIZE THE BIOPHARMACEUTICAL INDUSTRY
Owing to their vast potential in controlling disease-associated gene expression, RNAi therapeutics have emerged as a key segment of the market; several big pharma players have undertaken RNAi focused initiatives.
In addition to effective gene silencing, these candidates can be deployed for applications related to precision medicine. Studies have also demonstrated the safety of RNAi therapeutics for in systemic delivery, paving the way for systemic applications of the therapy. A number of novel and sophisticated technologies / platforms have been / are being developed to overcome the challenges associated with RNAi therapeutics, as well as further enhance their specificity and stability. Further, considering their high knockdown efficiency, high target specificity and extended silencing ability, RNAi has now been established as a powerful tool for gene silencing. It is worth highlighting, RNAi has potential applications in treating several viral infections and tumors in addition to its ability in gene function determination. However, despite the numerous benefits offered by RNAi therapies, developers often face concerns related to the stability and targeted delivery of their candidates. In order to mitigate the aforementioned challenges, several players have developed novel technologies and delivery systems to ensure target specific delivery of these molecules.
To request a sample copy / brochure of this report, please visit
https://www.rootsanalysis.com/reports/278/request-sample.html
With four approved drugs and several therapy candidates being evaluated in late stages of clinical development, the RNAi therapeutics domain presents a significant opportunity for biopharmaceutical developers. In addition, a number of RNAi therapeutics are being developed to target rare and genetic clinical conditions, such as Alpha 1-Antitrypsin Disease, Alport Syndrome, Amyloidosis and Muscular Dystrophy (Facioscapulohumeral Muscular Dystrophy and Oculopharyngeal Muscular Dystrophy). It is also worth highlighting that over 2,100 patents have been filed / granted, highlighting the continuous pace of ongoing innovation in this field. Given the high research activity and ongoing technology advancements, the RNAi therapeutics market is poised to grow at a steady pace in the foreseen future. An insightful technology competitiveness analysis, benchmarking RNAi technologies, based on supplier power (in terms of company size and years of experience) and key technology specifications. The analysis was designed to enable stakeholder companies to compare their existing capabilities within and beyond their respective peer groups and identify opportunities to achieve a competitive edge in the industry.
For additional details please visit https://www.rootsanalysis.com/reports/view_document/rnai-therapeutics-market/278.html or email [email protected]
You may also be interested in the following titles:
1. Targeted protein degradation market, 2022-2035
2. Cell Therapy Manufacturing Market, 2021-2030
3. Single-Use Upstream Bioprocessing Technology / Equipment Market, 2022-2035
About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected]
Contact:
Ben Johnson
+1 (415) 800 3415
+44 (122) 391 1091
#RNAi therapeutics#RNAi therapies#RNAi technologies#RNAi therapeutics market#Market Research#Market Insights#RootsAnalysis
0 notes
Text
VIRAL VACCINE CELL CULTURE MEDIA: OVERALL MARKET LANDSCAPE
Innovation is considered to be one of the key drivers of the pharmaceutical industry. Over the past few decades, various technological advances and a few fortuitous discoveries have significantly changed the practice of medicine. One such advancement that came into light was the development of vaccines, which have demonstrated significant therapeutic potential.
Over time, vaccine research has evolved significantly, which is now being driven by several innovative technologies, including those involving the use of recombinant deoxyribonucleic acid (DNA) and nucleic acids. Further, with the discovery of more disease targets, players engaged in vaccine development have shifted their focus towards the development of vaccines that target a myriad of disease indications other than infectious diseases. In order to mitigate the aforementioned challenges, pharma and biotech companies are gradually adopting viral vaccine cell culture media for vaccines manufacturing.
A vaccine is a biological substance that is used to stimulate the host’s immune system against a specific disease. It is worth highlighting those vaccines are also referred to as immunizers, due to their ability to take advantage of the host’s natural immune system to prevent illnesses. Generally, the vaccines contain a weakened or an inactivated (killed) form of a virus / a small (in virulent) part of the virus, which is called the antigen. Vaccines help the immune system recognize the antigen as a foreign entity or invading germ, thereby, resulting in the production of antibodies. This process aids the immune system in generating a memory against the specific pathogen so that if the host is attacked by the same pathogen in the future, the body can generate an illicit response.
To request a sample copy / brochure of this report, please visit link
https://www.rootsanalysis.com/reports/viral-vaccine-cell-culture-media-market/request-sample.html
Viral vaccines were first produced in the early 1940s, using embryonated chicken eggs to replicate a broad variety of viruses. Over 30 human vaccines, manufactured using this technique, have been licensed; however, the production capacity associated with this method was limited due to the unavailability of fertilized eggs. Further, in 1950s, an alternative technology based on animal cell culture, which used primary cells as substrate, was developed. Then, in the late 1960s, continuous cell lines were recognized as suitable hosts for human vaccine production, however, the first production process using this technique was established in 1977. One of the key objectives of this report was to evaluate the current opportunity and the future potential associated with the viral vaccine cell culture media market, over the coming decade. We have developed an informed estimate on the likely evolution of the market in the short to mid-term and long term, for the period 2022-2035.
Cell cultures can be broadly classified into two categories, namely adherent and suspension cell cultures.
§ Adherent Cell Culture: As the name suggests, these cells must be attached to a surface to grow. These cells can be cultured in flasks, roller bottles and other cell culture vessels capable of handling anchorage-dependent cell types. As most of the tissue-derived cells in the body require an extracellular matrix for growth and proliferation, this method provides scalable options, such as mimicking a microenvironment. In addition, some adherent platforms provide the benefit of visualization through a microscope.
§ Suspension Cell Culture: In this process, cells or cluster of cells are allowed to function and multiply in an agitated growth medium. Suspension cells can be cultured in small-scale vessels, such as spinner flasks or large-scale vessels (single-use bioreactors). These cells offer a vast range of scalability, thereby, making it a preferred option for manufacturers in order to increase their operational efficacy. In fact, the nutrients can be continually adjusted in these cell cultures, depending on their usage and need of the cells. However, suspension cell culture lacks the benefit of direct visualization. In addition, the shear force and stress exerted due to the continuous agitation of the media in suspension culture are detrimental to many cell types, especially anchorage-dependent primary and stem cells.
For additional details, please visit link https://www.rootsanalysis.com/reports/viral-vaccine-cell-culture-media-market.html or email [email protected]
You may also be interested in the following titles:
1. Targeted protein degradation market, 2022-2035
2. Cell Therapy Manufacturing Market, 2021-2030
3. Single-Use Upstream Bioprocessing Technology / Equipment Market, 2022-2035
About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected]
Contact:
Ben Johnson
+1 (415) 800 3415
+44 (122) 391 1091
#Viral vaccines#cell culture media#cell culture media market#vaccine#Market insights#Market Research#RootsAnalysis
0 notes
Text
The taste masking market is anticipated to grow at a steady pace till 2035
Driven by the growing need to enhance palatability of oral drugs and drug adherence among pediatric and geriatric population, the demand for novel and advanced taste masking and taste assessment technologies is expected to rise in the coming years.
London
Roots Analysis has announced the addition of “Taste masking and Taste Assessment Services and Technologies Market, 2022-2035” report to its list of offerings.
The inherent expertise of CMOs and CDMOs in taste masking and taste assessment of bitter drug formulations, along with capabilities to identify globally accepted tastes, develop flavor matching placebo formulations (for testing) having compliance with stringent regulatory guidelines and good clinical practices (GCPs) and proprietary technologies offering significant cost-benefits, have rendered outsourcing as a crucial aspect of taste masked formulation development and production.
Key Market Insights
Presently, 50 companies claim to offer taste masking and taste assessment services for oral drug formulations
Majority (40%, each) of the service providers are based in North America and Europe, followed by companies headquartered in Asia-Pacific (18%). A large proportion (34%) of these companies are large players, followed by small (31%) and mid-sized firms (27%).
Close to 30 technology platforms have been developed for taste masking and taste assessment of oral drug formulations
Majority (68%) of the technology platforms are used for taste masking and taste assessment of solid oral formulations (tablets, capsules, granules and powder), followed by liquid (10%) oral formulations (suspensions, syrups and solutions).
Partnership activity in this field has grown significantly between 2018 and 2021
The maximum number of partnerships were established in 2021 indicating a recent rise in the interest of players engaged in the field of taste masking and taste assessment. It is worth highlighting that majority of the agreements were related to acquisition, representing 46% of the total number of partnerships signed. This is followed by agreements signed for manufacturing of oral drug formulation (13%).
More than 460 patents have been filed / granted for taste masking and taste assessment techniques and technologies, since 2017
Close to 60% of the patent applications have been filed by various industry and non-industry players in this domain post 2018. It is worth noting that, around 75% of the patents were filed / granted in the US, followed by European Patent Office (25%).
North America is anticipated to capture larger share of the market by 2035
The taste masking market is likely to be driven by technology platforms that employ coating techniques. Further, solid formulations are likely to hold greater market share.
To request a sample copy / brochure of this report, please visit
https://www.rootsanalysis.com/reports/taste-masking-services-market/request-sample.html
The report features inputs from eminent industry stakeholders, who were very optimistic concerning the need of outsourcing of taste masking and taste assessment services in the coming decade. The report includes detailed transcripts of the discussions held with the following industry experts:
§ Phillipe Tschopp (Head of Business Development, Glatt Pharmaceutical Services)
§ David Tisi (Director of Technical Operations, Senopsys)
§ Brandon Keener (Business Development Associate, Adare Pharma Solutions)
For additional details, please visit https://www.rootsanalysis.com/reports/taste-masking-services-market.html or email [email protected]
You may also be interested in the following titles:
1. Targeted protein degradation market, 2022-2035
2. Cell Therapy Manufacturing Market, 2021-2030
3. Single-Use Upstream Bioprocessing Technology / Equipment Market, 2022-2035
About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected]
Contact:
Ben Johnson
+1 (415) 800 3415
+44 (122) 391 1091
#Taste masking#taste assessment#taste masking and taste assessment techniques#taste masking market#Market Research#Market Insights#RootsAnalysis
0 notes
Text
The biopharmaceutical excipient manufacturing market is projected to grow at an annualized rate of 5.8% during the period 2022-2035
The demand for biopharmaceutical excipients has grown considerably in the past few years; they play a critical role in biologics development by enhancing the solubility and bioavailability, controlling pH and tonicity of the active pharmaceutical ingredients (APIs)
Roots Analysis has announced the addition of “Biopharmaceutical Excipient Market” report to its list of offerings
Owing to the highly complex and capital-intensive manufacturing processes of biopharmaceutical excipients, many contemporary biologic developers prefer to rely on CMOs for the supply of GMP grade excipients. In order to cater to the growing demand for biopharmaceutical excipients across both clinical and commercial scales, CMOs with expertise in this field are anticipated to expand their capabilities and existing capacities in the coming years.
To order this 200+ page report, which features 75+ figures and 110+ tables, please visit
https://www.rootsanalysis.com/reports/biopharmaceutical-excipient-manufacturing-market.html
Key Market Insights
Over 40 companies, across the world, claim to offer biopharmaceutical excipients
Majority of the firms (34%) engaged in this domain are mid-sized players, followed by large firms (32%) and very large companies (19%). Close to 30% of the stakeholders were established post 2000. Further, 37% players are based in North America; within this region, the US emerged as a most prominent hub.
Partnership activity within this domain has grown at a CAGR of 70%, between 2016 and 2021
Over 40 agreements have been inked in the last 5 years in this domain; 32% of which were distribution agreements. Other popular types of partnership models adopted by players engaged in this domain include acquisitions (23%) and supply agreements (13%).
~ 40% rise in expansion initiatives in this field, during the period 2016-2021
More than 45% of such initiatives were focused on capacity expansion of manufacturing facilities, followed by those undertaken for expanding existing facilities (43%). It is worth mentioning that most of expansion initiatives (78%) were carried out in Europe and North America.
Approximately 95% of the total installed capacity is dedicated to commercial scale manufacturing
The remaining 5% of the installed capacity is focused on preclinical / clinical scale manufacturing of biopharmaceutical excipients. In addition, over 50% of the total current global, installed biopharmaceutical excipient manufacturing capacity is installed in Europe.
North America and Europe are anticipated to capture over 70% of the market share, by 2035
In addition, the market in Asia Pacific is likely to grow at a relatively faster pace (6.4%) in the long term. Further, in 2035, biopharmaceutical excipient manufacturing market for antibodies is expected to capture the majority share (~52%) of the total market.
To request a sample copy / brochure of this report, please visit
https://www.rootsanalysis.com/reports/biopharmaceutical-excipient-manufacturing-market.html
Key Questions Answered
§ Who are the key players engaged in biopharmaceutical excipient manufacturing?
§ Which global regions are considered as key hubs for biopharmaceutical excipient manufacturing?
§ What type of partnership models are commonly adopted by stakeholders in this industry?
§ What kind of expansion initiatives have been undertaken by biopharmaceutical excipient manufacturers?
§ What is current, global biopharmaceutical excipient manufacturing capacity of contract manufacturers?
§ How is the current and future market opportunity likely to be distributed across key market segments?
The financial opportunity within the protein design and engineering services market has been analyzed across the following segments:
§ Type of Biologic
§ Antibodies
§ Vaccines
§ Cell and Gene Therapies
§ Other Biologics
§ Type of Excipient
§ Carbohydrates
§ Polymers
§ Solubilizers / Surfactants
§ Polyols
§ Proteins / Amino Acids
§ Others
§ Company Size
§ Small
§ Mid-Sized
§ Large / Very Large
§ Scale of Operation
§ Preclinical
§ Clinical
§ Commercial
§ Key Geographical Regions
§ North America
§ Europe
§ Asia-Pacific
§ Latin America
§ MENA
§ Rest of the World
The report also features inputs from eminent industry stakeholders, according to whom, growing demand for biopharmaceutical excipients will drive the growth of manufacturers engaged in the biopharmaceutical excipient manufacturing domain, in the coming future.
The research includes profiles of key players (listed below); each profile features a brief overview of the company, financial information (if available), details related to its biopharmaceutical excipients portfolio, manufacturing facilities, recent developments, and an informed future outlook.
§ ABITEC
§ Avantor
§ BASF
§ Corden Pharma
§ DFE Pharma
§ Evonik
§ Kirsch Pharma
§ Merck KGaA
§ Pfanstiehl
§ Roquette
§ Spectrum Chemical Manufacturing
§ SPI Pharma
For additional details, please visit
https://www.rootsanalysis.com/reports/biopharmaceutical-excipient-manufacturing-market.html
or email [email protected]
You may also be interested in the following titles:
1. Gene Editing beyond CRISPR Market: Industry Trends and Global Forecasts, 2022-2035
2. Cell and Gene Therapy Bioassay Services Market: Industry Trends and Global Forecasts, 2022-2035
3. Thermostable Vaccines and Thermostable Biologics Market: Industry Trends and Global Forecasts, 2021-2035
4. Protein Design and Engineering Market: Industry Trends and Global Forecasts, 2021-2035
5. Next Generation Sequencing (NGS) Kits Market: Industry Trends and Global Forecast, 2021-2035
About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected]
Contact Information
Roots Analysis Private Limited
Ben Johnson
+1 (415) 800 3415
#biopharmaceutical excipients#biopharmaceutical excipients market#biopharmaceutical excipients market growth#biopharmaceutical excipients market size#market research#market insights#RootsAnalysis
0 notes
Text
SINGLE-USE SENSORS FOR BIOPROCESSING MARKET– CURRENT AND FUTURE MARKET POTENTIAL
Sensors are used to detect events or changes in environment parameters during a bioprocess control. These can be classified based on the type of variables measured, which include chemical variables (pH, dissolved oxygen or substrate or product concentration), physical variables (temperature, pressure, or viscosity), and biological variables (biomass concentration/morphology or biomass productivity). These sensors can also be classified on the basis of different principles used for measuring the variables, such as electrochemical sensors, optical chemosensor systems (known as optodes), optical spectroscopic sensors, and calorimetric sensors.
Further, sensors can be classified on the basis of their placement and integration within the bioreactor. sensors and controllers can be submerged in a liquid phase inside the bioreactor, submerged in a gas phase inside the bioreactor, in the exhaust gas stream, or placed with no physical connection to the bioreactor. Based on the abovementioned classification the sensors can be broadly categorized as follows:
§ At-line Sensors: These types of sensors provide data obtained by procedures performed after a short delay in the sampling and analysis. In case of filtration for high-performance liquid chromatography analysis and derivatization for gas chromatography, analytes are accessible after pre-treatment only.
§ In-line sensors (known as in situ sensors): These sensor types are in direct contact with the process, either with the liquid or gas phase. These help in providing data of the bioprocess in an online format.
Single-use sensors offer a number of benefits, such as ease of use, and convenience components, while providing the accuracy and robustness of traditional measurement techniques. Further improvements in analytical equipment, sensors and probes may facilitate process quantification and process analytical technology (PAT). Therefore, as bioprocessing processes becomes increasingly monitored by improved and novel detection methods (chemical, physical, and microbiological) and assays including single-use sensors, the output obtained can be further used for mathematical modeling and risk analysis.
The key advantages associated with SUT include reduced risk of cross-contamination, lower capital expenditure, and flexibility. Single-use bioprocessing systems are known to significantly reduce operation and manufacturing costs along with maintaining the overall quality of the product. The major advantages offered by single-use technologies are listed below:
§ Cost Reduction
§ Increased Productivity
§ Easy Disposal
§ Less Energy and Water Demand
§ Time Saving
§ Reduced Risk of Cross-Contamination
For additional details, please visit https://www.rootsanalysis.com/reports/single-use-sensors-for-bioprocessing.html
You may also be interested in the following titles:
1. Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market (4th Edition), 2021-2030
2. Global T-Cell (CAR-T, TCR, and TIL) Therapies Market (5th Edition), 2020-2030
3. Oncolytic Virus Therapy Market: Pipeline Review, Developer Landscape and Competitive Insights, 2020-2030
Contact:
Ben Johnson
+1 (415) 800 3415
#single-use bioprocessing probes and sensors market#single-use bioprocessing#single-use sensors#sensors and controllers#bioprocess control#marketresearch#Market Insights#RootsAnalysis
0 notes
Text
The single-use upstream bioprocessing technology market is projected to grow at a CAGR of 12% till 2035
Given the various benefits of single-use technology and the rising demand for biologics, the biopharmaceutical industry is gradually shifting from conventional manufacturing equipment to single-use upstream bioprocessing systems
Roots Analysis has announced the addition of “Single-use Upstream Bioprocessing Market, 2022-2035” report to its list of offerings.
The report features an extensive study on the extensive study of the current landscape and the likely future potential of container closure integrity testing services, over the next decade. The study also features an in-depth analysis, highlighting the capabilities of various industry stakeholders engaged in this field. In addition to other elements, the study includes:
§ A detailed assessment of the overall market landscape of single-use bioreactors based on a number of relevant parameters, such as scale of operation, type of cell culture system, type of cell culture, type of molecule, key features, application area and end users. In addition, it presents details of the companies developing single-use bioreactors, highlighting their year of establishment, company size, and geographical presence.
§ A detailed assessment of the overall market landscape of single-use mixers based on a number of relevant parameters, such as scale of operation, type of mixing system, type of molecule, key features and application area. In addition, it presents details of the companies developing single-use bioreactors, highlighting their year of establishment, company size, and geographical presence.
§ A detailed assessment of the overall market landscape of single-use sensors, based on several relevant parameters, such as type of sensor, type of bioprocessing, measurement range, operating temperature, sterilization technique, material used and application area. In addition, the chapter presents details of the companies involved in the development of single-use sensors, including information on their year of establishment, company size, and geographical presence.
§ A tabulated section presenting the overall market landscape of other single-use technologies, such as media bags and containers, filters, sampling systems and connectors.
§ A detailed competitiveness analysis of single-use bioreactors, single-use mixers and single-use sensors, taking into consideration several relevant parameters. The parameters include the product applicability and product strength.
§ Tabulated profiles of the key players providing single-use upstream bioprocessing technologies, which are headquartered in North America, Europe and Asia-Pacific. Each profile includes an overview of the company, information on the financial performance (if available), service portfolio, product portfolio, recent developments, and an informed future outlook.
§ An in-depth analysis of various patents that have been filed / granted for single-use upstream bioprocessing technology, till December 2021, highlighting key trends associated with these patents, across type of patents, publication year, application year, issuing authorities involved, type of organizations, emerging focus area, patent age, CPC symbols, leading patent assignees (in terms of number of patents granted / filed), patent characteristics and geography. It also includes a detailed patent benchmarking and an insightful valuation analysis.
§ A detailed brand positioning analysis of the key industry players (including single-use bioreactor developers, single-use mixers developers and single-use sensors developers), highlighting the current perceptions regarding their proprietary products by taking into consideration several relevant aspects, such as experience of the manufacturer, number of products offered, product diversity, and number of patents published.
§ An insightful case study depicting the cost saving potential of single-use upstream bioprocessing technology. It also discusses about the time saving potential associated with the single-use upstream bioprocessing technology.
§ An informed estimate on the current and future demand-supply scenario for single-use upstream bioprocessing technologies, for the period 2022-2035.
By 2035, the financial opportunity within the single-use upstream bioprocessing technology market has been analysed across the following segments:
§ Analysis by Scale of Operation
Press Release: Variation 1 (Format 2)
Pre-clinical and Clinical
Commercial
§ Analysis by Type of Equipment
Single-use Bioreactor
Single-use Mixing System
Single-use Media Bags
Single-use Filters
Single-use Sampling System
Single-use Connectors
Single-use Membrane Adsorbents
Other Single-use Technology
§ Analysis by Geographical Regions
North America
Europe
Asia Pacific
Latin America
MENA
Key companies covered in the report:
§ Avantor
§ Cytiva
§ Eppendorf
§ Merck
§ Pall
§ Premas Biotech
§ Reprocell
§ Saint Gobain
§ Sartorius Stedim Biotech
§ Satake Multimix
§ Thermo Fisher Scientific
For more information, please click on the following link:
https://www.rootsanalysis.com/reports/single-use-upstream-bioprocessing-technology-market.html
Other recent offerings:
1. Single-use Sensors for Bioprocessing Market: Industry Trends and Global Forecast, 2021-2035
2. Continuous Manufacturing Equipment Providers Market: Industry Trends and Global Forecast, 2021-2030
3. Single-use Bioreactor Market (2nd Edition): Industry Trends and Global Forecasts, 2021-2030
4. Bioprocess Controller and Automation System Market: Industry Trends and Global Forecast, 2021-2030
About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected]
Contact Information
Roots Analysis Private Limited
Ben Johnson
+1 (415) 800 3415
#single-use bioprocessing market#upstream bioprocessing#upstream single use bioprocessing systems#bioprocessing technologies#single use bioprocessing#marketresearch#Market Insights#RootsAnalysis
0 notes
Text
The companion diagnostics development services market, is anticipated to grow at a CAGR of over 10%, till 2035
Given the various challenges associated with co-development of companion diagnostics and drug / therapy, drug developers prefer to rely on third-party service providers that offer customized services and advanced technologies.
Roots Analysis has announced the addition of “Companion Diagnostics Development Services Market (2nd Edition), 2022-2035” report to its list of offerings.
The growing pipeline of patient-centric targeted therapies has led to a surge in demand for companion diagnostics; these tests are known to improve the success rates of late-stage trials by almost three-fold. The development and approval of these FDA classified high-risk devices requires multidisciplinary expertise and an established network of R&D and production facilities that can be accessed through service providers.
Key Market Insights
Over 150 companies claim to offer companion diagnostics development services, globally
Nearly 60% of the aforementioned players are based in North America, followed by the players located in Europe (30%). Further, this segment of the industry is dominated by the presence of mid-sized players (51-200 employees), which represent 40% of the total service providers.
Nearly 15% players claim to act as one-stop shops, offering services, ranging from biomarker discovery and development to manufacturing and commercialization
Most of the service providers (127) provide assay development services, followed by companies (124) offering services for biomarker discovery / identification. Further, NGS is the most popular technique, employed by over 100 service providers.
Over 90 companies are actively involved in the development of companion diagnostics
Nearly 91% of the total tests can detect mutations in a single biomarker. Amongst these, ErbB gene family (HER-2 and EGFR genes), PD-L1 genes, RAS gene family (KRAS and NRAS genes), BRCA gene family (BRCA1 and BRCA2) and BRAF emerged as the key genes which are assessed by majority of the companion diagnostics.
Partnership activity in this domain has increased at a CAGR of ~25%, between 2017 and 2021
Mergers and acquisitions, product development agreements and product development and commercialization agreements account for more than 60% of the total number of deals inked during the given time period. It is worth highlighting that nearly 25% of the total number of deals were signed in 2021. Further, the maximum number (177) of partnerships have been inked for companion diagnostics being developed for the treatment of oncological disorders.
North America is expected to capture ~60% share in the companion diagnostics development services market by 2035
Owing to the high costs associated with the clinical validation of companion diagnostics, a significant proportion (~46%) of service revenues is generated from this step, in 2035. In terms of analytical technique used, service contracts involving NGS are anticipated to contribute to more than 35% of the total service revenues generated in 2035. Further, close to 90% of the total service revenues, in 2035, are generated from companion diagnostics development projects for cancer indications.
To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/297/request-sample.html
One of the key objectives of the report was to estimate the existing companion diagnostics market size and the potential future growth opportunities for companion diagnostics development service providers. Based on multiple parameters, such as the service cost of various steps involved in companion diagnostics development and manufacturing, and partnerships inked in the last few years for outsourcing of such operations, we have developed informed estimates on the evolution of the market for the time period 2022- 2035. An insightful analysis of companies segregated on the basis of their likelihood to enter into collaborations with companion diagnostics service providers. The chapter features a list of 300+ drug developers sponsoring clinical trials of therapies targeting several disease-specific biomarkers. The players have been shortlisted based on relevant parameters, namely number of biomarker-focused clinical trials sponsored and the time to market their proprietary personalized medicine products.
Key Questions Answered
§ Who are the leading players offering services for the development of companion diagnostics?
§ Which are the key geographies where companion diagnostics development service providers are located?
§ Which analytical techniques are used by the service providers engaged companion diagnostics development services market?
§ Who are the leading companion diagnostics developers?
§ Which biomarkers are most commonly targeted by the marketed products / investigational programs?
§ Which partnership models are commonly adopted by stakeholders offering companion diagnostics development services?
§ Which drug developers are most likely to partner with the service providers to seek their expertise?
§ What are the key value drivers of the merger and acquisition activity within companion diagnostics development services market?
§ Which biomarker-focused targeted drugs developed by big pharmaceutical companies are likely to be administered with companion diagnostics?
§ How is the current and future opportunity likely to be distributed across key market segments?
The financial opportunity within the companion diagnostics development services market has been analyzed across the following segments:
§ Type of Service Offered
§ Feasibility Studies
§ Assay Development
§ Analytical Validation
§ Clinical Validation
§ Manufacturing
§ Type of Technique Used
§ NGS
§ PCR
§ ICH / ISH
§ Liquid Biopsy
§ Others
§ Therapeutic Areas
§ Oncological
§ Non-oncological
§ Key Geographical Regions
§ North America
§ Europe
§ Asia-Pacific and Rest of the World
The report also features detailed transcripts of discussions (in reverse chronological order) held with the following experts:
§ Mike Klein (Chief Executive Officer, Genomenon)
§ Mark Kiel (Founder and Chief Scientific Officer, Genomenon)
§ Candace Chapman (Vice President of Marketing, Genomenon)
§ Anton Iliuk (President and Chief Technology Officer, Tymora Analytical Operations)
§ Paul Kortschak (Former Senior Vice President, Novodiax)
§ Pablo Ortiz (Chief Executive officer, OWL Metabolomics)
§ Lawrence Weiss (Former Chief Scientific Officer, NeoGenomics Laboratories)
The research includes detailed profiles of key players (listed below), each profile features an overview of the company, its financial information (if available), drug portfolio, details on recent developments, and an informed future outlook.
§ Almac Diagnostic Services
§ BGI Genomics
§ Biocartis
§ Cerba Research
§ Geneuity Clinical Research Services
§ Interpace Biosciences
§ Labcorp (formerly known as Covance)
§ MEDICAL & BIOLOGICAL LABORATORIES (MBL)
§ MEDx (Suzhou) Translational Medicine (formerly known as QIAGEN (Suzhou) Translational Medicine)
§ MLM Medical Labs
§ Novogene
§ Q2 Solutions
§ Quest Diagnostics
§ ResearchDx
For additional details, please visit
https://www.rootsanalysis.com/reports/view_document/companion-diagnostics-services/297.html or email [email protected]
You may also be interested in the following titles:
1. Targeted protein degradation market, 2022-2035
2. Cell Therapy Manufacturing Market, 2021-2030
3. Single-Use Upstream Bioprocessing Technology / Equipment Market, 2022-2035
About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected]
Contact:
Ben Johnson
+1 (415) 800 3415
+44 (122) 391 1091
#Companion Diagnostics#companion diagnostics development#companion diagnostics market size#personalized medicine#market insights#market research#RootsAnalysis
0 notes
Text
MORE THAN 740 RNA EXTRACTION AND PURIFICATION KITS ARE COMMERCIALLY AVAILABLE IN THE MARKET; AROUND 70% OF THESE KITS DEPLOY SPIN COLUMN TECHNOLOGY FOR EXTRACTION AND PURIFICATION OF RNA
Amongst the total players involved in the development of RNA extraction and purification kits and reagents, majority of the players engaged in the development of RNA extraction and purification kits were established between 1981-2000.
During our research, we were able to identify more than 60 developers were involved in the development of RNA extraction and purification kits and reagents. The RNA extraction and purification kits market is currently dominated by the presence of small companies. This is followed by the presence of well-established players in this domain.
Further, most of the manufacturers of RNA extraction kits are headquartered in North America. Within this region, the US has emerged as the most prominent region, having the highest number of manufacturers. This is followed by the number of stakeholders headquartered in Asia-Pacific, with China and India being the base of operations for seven companies engaged in this domain. As can be observed in the figure, majority of the kits employ spin column technology for RNA extraction and purification. This is followed by the number of kits that employ magnetic beads technologies for the extraction and RNA purification. Further, maximum number of the kits have the ability to extract total RNA, followed by the kits that can extract viral RNA.
To request a sample copy / brochure of this report, please visit this
https://www.rootsanalysis.com/reports/rna-extraction-and-purification/request-sample.html
It is evident from the figure that over 80% of the RNA isolated using RNA extraction and purification kits are used for PCR / RT-PCR applications, whereas 49% isolated RNA are used for blotting applications. It is worth mentioning that close to 50% kits are used to isolate RNA for SARS-CoV-2 analysis. With the increasing adoption of molecular diagnostics and introduction of novel and advanced RNA extraction and purification techniques, the RNA isolation and purification market is anticipated to witness steady growth in the coming years.
For additional details, please visit
https://www.rootsanalysis.com/reports/rna-extraction-and-purification.html
You may also be interested in the following titles:
1. Targeted protein degradation market, 2022-2035
2. Cell Therapy Manufacturing Market, 2021-2030
3. Single-Use Upstream Bioprocessing Technology / Equipment Market, 2022-2035
About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected]
Contact:
Ben Johnson
+1 (415) 800 3415
+44 (122) 391 1091
#RNA extraction#RNA extraction kits#RNA purification#RNA isolation and purification market#market insights#market research#RootsAnalysis
0 notes
Text
The automatic sampling systems market is anticipated to grow at a CAGR of over 15% by 2035
Given the advanced features and cost saving potential, automatic sampling systems have been widely adopted by various stakeholders in biopharmaceutical industry, to monitor data in real-time and reduce deviations associated with manual sampling.
London
Roots Analysis has announced the addition of “Automatic Sampling in Biopharmaceuticals Applications and the Measurement of CQA, 2022-2035” report to its list of offerings.
The automatic sampling systems have diverse applications, including bioprocess / analyte monitoring, data management and advanced process control / feedback control, in biotechnology and pharmaceutical industries. As a result, several bioprocess equipment developers have been engaged in the development of user-friendly, controlled, and automated systems to increase the productivity and flexibility of the bioprocess. During each stage of biopharmaceutical manufacturing process, it is essential to ensure that the bioprocess variables and parameters are under control. Sampling is considered to be an important step in the bioprocess. However, there are several challenges associated with conventional, manual aseptic sampling technique, such as high risk of contamination of the sample, high labor costs, operator-to-operator deviations during sampling and sample preparation, lower sample frequency rates and no real-time availability of data. This has created a demand for systems that allow aseptic sampling and handling of samples, reduce errors, and increase reproducibility.
Key Market Insights
Currently, more than 55 automatic sampling systems are available in the market
Majority (71%) of the automatic sampling systems are capable of on-line monitoring, followed by off-line (22%) and at-line monitoring (7%). It is worth noting that around 25% of the automatic sampling systems offer multiplexer module for withdrawing the sterile samples, followed by systems containing routing module (23%) that can transfer the sample to various analyzers.
Around 45 companies are presently engaged in the manufacturing of automatic sampling systems, globally
The automatic sampling industry is dominated by the presence of mid-sized players (51-200 employees), representing more than 40% of the total automatic sampling system manufacturers. Further, about 15% firms were established post-2010. In addition, majority (54%) of the players engaged in this domain are based in Europe, followed by North America (32%).
Close to 20 automatic sample collection / preparation systems are presently available
Majority of the automatic sample collection / preparation systems (84%) are stand-alone systems. This is followed by integrated systems which capture 16% share in this domain. Further, most of these systems (nearly 40%) are being used in the pharmaceutical industry, followed by the biotechnology industry (35%).
Over 400 patents related to automatic sampling in biopharmaceutical industry have been filed / granted, since 2016
Owing to the increase in research and development efforts led by several industry and non-industry players engaged in this domain, close to 50% of patent applications have been filed post-2016. It is worth noting that 56% patents related to automatic sampling systems were filed / granted in the US alone.
Partnership activity in this field has increased at a CAGR of nearly 30%, between 2017 and 2021
Around 45% of the deals were inked in 2020 and 2021. Majority of the instances captured in the report (~40%) were product distribution agreements. Further, most of the agreements were inked with players based in North America (nearly 70%).
Over 25 global events related to automatic sampling systems were organized in the past couple of years
Majority (~80%) of the events related to automatic sampling systems, were organized virtually in order to comply with the guidelines in the ongoing COVID-19 pandemic. It is worth highlighting that the agendas of the events organized post-2020 include discussions on the potential, advancements and challenges associated with these systems in various bioprocessing operations.
North America is anticipated to capture over 50% of the global market share for automatic sampling systems, by 2035
The market will be primarily driven by sales of automatic sampling systems capable of on-line monitoring (59%). Further, systems which are used in upstream bioprocessing method are expected to occupy a larger share (60%) of the overall market (in terms of sales-based revenues), by 2035.
To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/automatic-sampling-market/request-sample.html
Key Questions Answered
§ Who are the key players engaged in the development of automatic sampling systems?
§ What is the relative competitiveness of different automatic sampling system manufacturers?
§ Who are the leading manufacturers involved in the automatic sample collection / preparation systems market?
§ How has the intellectual property landscape of automatic sampling systems evolved over the years?
§ What are the key agenda items being discussed in the various global events / conferences related to automatic sampling systems?
§ Which partnership models are most commonly adopted by stakeholders engaged in the automatic sampling industry?
§ How is the current and future market opportunity, likely to be distributed across key market segments?
The financial opportunity within the automatic sampling systems market has been analyzed across the following segments:
§ Type of Monitoring Method
§ On-line
§ Off-line
§ At-line
§ Bioprocessing Method
§ Upstream
§ Downstream
§ Working Volume
§ Less than 10 mL
§ 10-50 mL
§ 51-100 mL
§ More than 100 mL
§ Scalability
§ Lab
§ Pilot
§ Commercial
§ Key Geographical Regions
§ North America
§ Europe
§ Asia-Pacific and Rest of the World
The research also includes detailed profiles of the key players (listed below) engaged in the manufacturing of automatic sampling systems; each profile features an overview of the company, its financial information (if available), details on product portfolio, recent developments and an informed future outlook.
§ Agilent Technologies
§ Cytiva
§ Mettler Toledo
§ Pall Corporation
§ Shimadzu
§ Xylem
For additional details, please visit
https://www.rootsanalysis.com/reports/automatic-sampling-market.html
or email [email protected]
You may also be interested in the following titles:
1. Targeted protein degradation market, 2022-2035
2. Cell Therapy Manufacturing Market, 2021-2030
3. Single-Use Upstream Bioprocessing Technology / Equipment Market, 2022-2035
About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected]
Contact:
Ben Johnson
+1 (415) 800 3415
+44 (122) 391 1091
#Automatic Sampling#biopharmaceutical manufacturing#aseptic sampling technique#aseptic sampling#market research#market insights#RootsAnalysis
0 notes
Text
The novel antibody therapies market for advanced stage drugs is anticipated to grow at a CAGR of 36% by 2035
Owing to the recent approval of therapies, such as Elzonris®, Pluvicto®, there has been a substantial increase in the R&D activity to evaluate the use of novel antibody therapy candidates for the treatment of a variety of disease indications
Roots Analysis has announced the addition of “Novel Antibody Therapies Market, 2022-2035” report to its list of offerings.
Antibodies are the key components of immune system that bind to specific markers on cells or tissues, thereby offering first line of defense against multiple disorders. This has opened a new target space for the development of antibody therapeutics and techniques, facilitating tools to uniquely distinct malignantly transformed cells from regular cells.
To request a sample copy / brochure of this report, please visit
https://www.rootsanalysis.com/reports/novel-antibody-therapies-market/request-sample.html
Key Market Insights
Presently, 140+ novel antibody therapies have been marketed / are being evaluated across different phases of development for the treatment of various disease indications
Till date, five novel antibody therapies have been marketed and close to 80% of the pipeline candidates are under clinical evaluation. It is worth mentioning that most of the drug candidates are immunotoxins (34%), followed by immunocytokines (32.5%). Majority of these therapies are under clinical trials for the treatment of lymphoma (22) followed by solid tumors (19) and leukemia (18).
Around 60 industry and non-industry players are engaged in the development of novel antibody therapies, globally
North America has emerged as the hub, featuring the presence of approximately 60% developers. The market is currently dominated by the presence of small players (27%). Interestingly, 16% of the players are big pharma companies engaged in the development of such therapeutics for multiple target indications.
More than 550 clinical trials have been registered for the evaluation of novel antibody therapies, worldwide
The clinical research activity, in terms of number of trials registered, is reported to have increased at a steady CAGR of 8%, during the period 2016-2021. Of the total number of trials registered, close to 60% have already been completed, while 25% of the studies are actively recruiting participants.
Close to 600 articles related to novel antibody therapies, have been published in reputed scientific journals, since 2017
More than 95% of the articles focused on novel antibody therapies were published post-2019. Popular journals that have published multiple articles include Cancer, Frontiers in Immunology, International Journal of Molecular Sciences and Scientific Reports.
Over 4,600 patents have been filed / granted related to novel antibody therapies, since 2017
More than 1,150 patents were filed / granted in 2021. Further, around 56% of the patents were filed in North America. It is worth highlighting that majority of the patents were granted / filed by prominent industry / non-Industry players, such as Novartis, Hoffmann la Roche, Immatics Biotechnologies
and Pfizer.
Partnership activity in this field has increased at a CAGR of over 55%, since 2018
Around 50% of the reported deals were established post-2021, indicating a recent rise in the interest of players engaged in this domain. It is worth highlighting that majority of the agreements were supply agreements (19%), followed by product development and commercialization agreements (15%).
North America is anticipated to capture larger share of the phase III novel antibody therapies market by 2035
Around 40% of the market revenues are likely to be generated from the sales of drug candidates being evaluated in phase III for bladder cancer. Further, therapies designed for intravenous route of administration are expected to occupy close to 70% of the overall market.
For additional details, please visit https://www.rootsanalysis.com/reports/novel-antibody-therapies-market.html or email [email protected]
You may also be interested in the following titles:
1. Targeted protein degradation market, 2022-2035
2. Cell Therapy Manufacturing Market, 2021-2030
3. Single-Use Upstream Bioprocessing Technology / Equipment Market, 2022-2035
About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected]
Contact:
Ben Johnson
+1 (415) 800 3415
+44 (122) 391 1091
#Novel Antibody Therapies Market#antibody therapies#immunotoxins#novel antibody therapies#Market Insights#Market Research#RootsAnalysis
0 notes
Text
Rise in Demand for Treatment Modalities, Coupled to the Requirement of Complex Manufacturing Equipment and Expertise, Medical Device Developers have been Compelled to Outsource their Manufacturing Operations to Contract Service Providers
The in-house development of peptide API requires necessary expertise and capabilities, including design, construction and maintenance of a facility which demands significant capital investments. Therefore, several small drug developers and, at times, certain pharma giants as well, have started outsourcing their manufacturing operations to contract service providers.
Over the years, the popularity of biologics has led to an evident shift in the focus of pharmaceutical companies, from traditional interventions towards more complex and advanced pharmacological interventions, such as peptide therapeutics. Since the discovery of insulin, the peptide therapeutics market has evolved significantly. The increasing demand for companies capable of offering manufacturing and, in certain cases, development services to biopharmaceutical players has resulted in the establishment of several CMOs. Most of these contract service providers have profound experience in niche and emerging areas. The innate expertise and availability of the required capabilities and infrastructure enables CMOs to effectively fulfil the requirements of their clients, eliminate costly oversights and, thereby, reduce chances of failure. As pharma companies resume full-scale operation after the COVID-19 outbreak, the demand for large-scale peptide therapeutics contract API manufacturing is expected to increase significantly.
To request a sample copy / brochure of this report, please visit
https://www.rootsanalysis.com/reports/305/request-sample.html
In fact, drug developers are actively collaborating with CMOs that offer improved technology platforms to increase the bioavailability of peptide drugs and enhance the efficacy of the production process. The aforementioned factors are likely to drive growth of the contract manufacturing and provide lucrative opportunities to CMOs in the near future. Presently, XX% of the total capacity is available with contract manufacturers catering to the needs for commercial scale operations. Further, majority (XX%) of the peptide API contract manufacturing capacity is installed in facilities based in Europe. However, we believe that, in order to cope up with the increasing demand and maintain a competitive advantage, CMOs should further enhance their existing capabilities and capacities, as well as adopt innovative and efficient production technologies.
For additional details, please visit
https://www.rootsanalysis.com/reports/view_document/peptide-therapeutics-manufacturing/305.html or email [email protected]
You may also be interested in the following titles:
1. Targeted protein degradation market, 2022-2035
2. Cell Therapy Manufacturing Market, 2021-2030
3. Single-Use Upstream Bioprocessing Technology / Equipment Market, 2022-2035
About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected]
Contact:
Ben Johnson
+1 (415) 800 3415
+44 (122) 391 1091
#peptide therapeutics#peptide therapeutics market#contract API manufacturing#peptide API#Market Research#Market Insights#RootsAnalysis
0 notes
Text
DRIVEN BY THE INCREASED ADOPTION AND RISING UNMET NEED ASSOCIATED WITH PARENTERAL DRUGS, INDUSTRY STAKEHOLDERS HAVE MADE SIGNIFICANT INVESTMENTS TOWARDS THE DEVELOPMENT OF ORALLY ADMINISTERED PROTEIN AND PEPTIDE THERAPEUTICS
Over the years, advances in recombinant DNA technology and ex vivo synthesis of biomolecules have led to the development and (in some cases) approval of several protein / peptide-based therapeutics.
Considering the therapeutic advantages associated with proteins and peptides, this field has witnessed significant activity; researchers are actively evaluating orally bioavailable interventions. However, owing to their inherently complex structure and comparatively low stability (in in vivo conditions), proteins / peptides are predominantly administered parenterally. Recent strides in drug delivery solutions have enabled scientists to successfully explore and exploit alternative routes of drug delivery, such as transdermal, intranasal, pulmonary and oral, for protein / peptide-based therapeutics. Of these, the oral route of delivery is considered to be the most patient-friendly. This has led several companies to invest in the development of orally administered biologics. The delivery of proteins and peptides utilizes the following routes of administration. Since the approval of the first protein / peptide-based therapy (recombinant human insulin) in 1982, there has been a substantial increase in the R&D initiatives focused on such products. Earlier, majority of the biologics were administered subcutaneously. However, with the technological advancements in delivery formulations, oral delivery of therapeutic interventions has gained significant traction, prompting stakeholders to leverage their expertise in the development of orally administrable proteins / peptides.
To request a sample copy / brochure of this report, please visit
https://www.rootsanalysis.com/reports/192/request-sample.html
Although studies have reported that over XX oral drug delivery technologies have been designed so far, our research indicates that only XX% of the aforementioned technologies are currently being used to develop therapeutic proteins / peptides. Owing to the numerous advantages of oral drug delivery, including ease of administration, minimal pain and risk of drug reaction, and self-administration, we are led to believe that the oral proteins / peptide therapeutics market is anticipated to witness significant growth in the coming future.
For additional details, please visit https://www.rootsanalysis.com/reports/view_document/oral-proteins-and-peptides-market/192.html or email [email protected]
You may also be interested in the following titles:
1. Targeted protein degradation market, 2022-2035
2. Cell Therapy Manufacturing Market, 2021-2030
3. Single-Use Upstream Bioprocessing Technology / Equipment Market, 2022-2035
About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected]
Contact:
Ben Johnson
+1 (415) 800 3415
+44 (122) 391 1091
#oral drug#oral delivery#oral proteins#proteins and peptides#marketresearch#market insights#RootsAnalysis
0 notes
Text
The taste masking market is anticipated to grow at a steady pace till 2035
Driven by the growing need to enhance palatability of oral drugs and drug adherence among pediatric and geriatric population, the demand for novel and advanced taste masking and taste assessment technologies is expected to rise in the coming years.
London
Roots Analysis has announced the addition of “Taste masking and Taste Assessment Services and Technologies Market, 2022-2035” report to its list of offerings.
The inherent expertise of CMOs and CDMOs in taste masking and taste assessment of bitter drug formulations, along with capabilities to identify globally accepted tastes, develop flavor matching placebo formulations (for testing) having compliance with stringent regulatory guidelines and good clinical practices (GCPs) and proprietary technologies offering significant cost-benefits, have rendered outsourcing as a crucial aspect of taste masked formulation development and production.
Key Market Insights
Presently, 50 companies claim to offer taste masking and taste assessment services for oral drug formulations
Majority (40%, each) of the service providers are based in North America and Europe, followed by companies headquartered in Asia-Pacific (18%). A large proportion (34%) of these companies are large players, followed by small (31%) and mid-sized firms (27%).
Close to 30 technology platforms have been developed for taste masking and taste assessment of oral drug formulations
Majority (68%) of the technology platforms are used for taste masking and taste assessment of solid oral formulations (tablets, capsules, granules and powder), followed by liquid (10%) oral formulations (suspensions, syrups and solutions).
Partnership activity in this field has grown significantly between 2018 and 2021
The maximum number of partnerships were established in 2021 indicating a recent rise in the interest of players engaged in the field of taste masking and taste assessment. It is worth highlighting that majority of the agreements were related to acquisition, representing 46% of the total number of partnerships signed. This is followed by agreements signed for manufacturing of oral drug formulation (13%).
More than 460 patents have been filed / granted for taste masking and taste assessment techniques and technologies, since 2017
Close to 60% of the patent applications have been filed by various industry and non-industry players in this domain post 2018. It is worth noting that, around 75% of the patents were filed / granted in the US, followed by European Patent Office (25%).
North America is anticipated to capture larger share of the market by 2035
The taste masking market is likely to be driven by technology platforms that employ coating techniques. Further, solid formulations are likely to hold greater market share.
To request a sample copy / brochure of this report, please visit
https://www.rootsanalysis.com/reports/taste-masking-services-market/request-sample.html
The report features inputs from eminent industry stakeholders, who were very optimistic concerning the need of outsourcing of taste masking and taste assessment services in the coming decade. The report includes detailed transcripts of the discussions held with the following industry experts:
§ Phillipe Tschopp (Head of Business Development, Glatt Pharmaceutical Services)
§ David Tisi (Director of Technical Operations, Senopsys)
§ Brandon Keener (Business Development Associate, Adare Pharma Solutions)
For additional details, please visit https://www.rootsanalysis.com/reports/taste-masking-services-market.html or email [email protected]
You may also be interested in the following titles:
1. Targeted protein degradation market, 2022-2035
2. Cell Therapy Manufacturing Market, 2021-2030
3. Single-Use Upstream Bioprocessing Technology / Equipment Market, 2022-2035
About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected]
Contact:
Ben Johnson
+1 (415) 800 3415
+44 (122) 391 1091
#Taste masking#taste assessment#taste masking and taste assessment techniques#taste masking market#Market Research#Market Insights#RootsAnalysis
0 notes